BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

The first week of 2026 has signaled a tectonic shift in the global financial landscape, as a wave of multi-billion dollar acquisitions has effectively ended the deal-making drought of the previous two...

Topics Artificial Intelligence

The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity

January 06, 2026

A new year brings new opportunities to grow your wealth on Wall Street.

Topics Artificial Intelligence Economy Energy

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a 'Decent Value' Candidate ↗

January 02, 2026

Via Chartmill

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal ↗

December 19, 2025

Via Stocktwits

10 Magnificent Stocks That Can Make You Richer in 2026 ↗

January 05, 2026

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Topics Economy Stocks World Trade

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

Topics Economy Intellectual Property

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the afternoon session after the stock's positive momentum continued as the company agreed to acquire Amicus Therapeutics...

Topics ETFs Intellectual Property

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

December 23, 2025

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 19% in the afternoon session after the company announced it agreed to acquire Amicus Therapeutics for approximately $4.8 billion...

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

December 19, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Topics Economy

Which stocks are gapping on Friday? ↗

December 19, 2025

Via Chartmill

1 Oversold Stock Primed to Rebound and 2 That Underwhelm

December 15, 2025

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

December 08, 2025

BioMarin Pharmaceutical (BMRN) presents a compelling value investment case, trading at a significant discount to its biotech peers while showing strong profitability, financial health, and growth...

Via Chartmill

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

Topics Regulatory Compliance

December 03, 2025

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

Topics Regulatory Compliance

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

Topics Regulatory Compliance

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

BioMarin Pharmaceutical currently trades at $55.56 per share and has shown little upside over the past six months, posting a small loss of 4.4%. The stock also fell short of the S&P 500’s 11.5% gain...

2 Reasons to Like BMRN and 1 to Stay Skeptical

November 24, 2025

Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks

Topics Stocks

November 23, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with BioMarin...

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

Topics Artificial Intelligence

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Over the past six months, BioMarin Pharmaceutical’s stock price fell to $51.76. Shareholders have lost 11.5% of their capital, which is disappointing considering the S&P 500 has climbed by 13.7%. This...

Topics Economy Government World Trade

BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?

November 20, 2025

Shares in the biotech company have surged on news of a big pharma takeover.

Topics Stocks

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗

November 20, 2025

The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market

November 14, 2025

The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the...

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Topics Artificial Intelligence ETFs Economy

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

November 12, 2025

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain momentum.

Topics Artificial Intelligence Stocks

3 Cash-Producing Stocks with Promising Prospects

November 09, 2025

This Zimmer Biomet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

November 06, 2025

Via Benzinga

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

November 05, 2025

BioMarin presents a strong value investment case with low valuation multiples, robust profitability, and a healthy balance sheet, all while showing solid growth potential.

Via Chartmill

The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call

November 03, 2025

BioMarin Pharmaceutical’s third quarter results reflected steady top-line growth, with management highlighting enzyme therapies and the Skeletal Conditions business as main contributors. CEO Alexander...

Although the company recorded higher sales overall, it's decided to divest one of its products.

Topics Earnings

Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday ↗

October 28, 2025